NCT06926621View on ClinicalTrials.gov

A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 28, 2025

Primary Completion Date

July 24, 2028

Study Completion Date

July 24, 2028

Conditions
Myotonic Dystrophy Type 1 (DM1)
Interventions
DRUG

VX-670

Solution for intravenous administration.

Trial Locations (6)

Unknown

Wesley Research Institute, Auchenflower

Neuroscience Clinical Trials Unit, Alfred Brain, Melbourne

Altasciences Montreal, Montreal

Montreal Neurological Institute-Hospital, Montreal

University of Ottawa, Ottawa

Leonard Wolfson Experimental Neurology Centre CRF, London

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY